<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419989</url>
  </required_header>
  <id_info>
    <org_study_id>NTM-OB-17 (PATIENCE PART B)</org_study_id>
    <nct_id>NCT02419989</nct_id>
  </id_info>
  <brief_title>PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis</brief_title>
  <acronym>PATIENCE</acronym>
  <official_title>Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an
      increasingly common finding, and the lack of an evidenced-based approach to treatment of NTM
      disease has been identified as one of the greatest unmet needs within the CF community.
      Current evidence predicts that the prevalence of NTM will remain relatively high in the CF
      population. Approaches to NTM disease treatment differ widely between centers, and expected
      outcomes are not known. This study is observational and follows current best practices. The
      study will help define response to treatment, and collect relevant data associated with
      treatment of NTM disease to build a framework for future therapeutic trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion who adhere to the protocol based on: number of respiratory cultures obtained per year, withdrawals or major deviations from protocol</measure>
    <time_frame>12 months following end of antibiotic treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and combinations of NTM treatment regimens received</measure>
    <time_frame>At end of treatment interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion requiring antibiotic course change due to intolerance or lack of microbiological conversion (i.e. eradication from sputum)</measure>
    <time_frame>At end of treatment interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion who complete ≥ 12 months of treatment since first negative culture</measure>
    <time_frame>At end of treatment interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion eradicating NTM defined by ≥ 12 months of negative cultures since end of treatment</measure>
    <time_frame>12 months following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability between sites for NTM eradication success</measure>
    <time_frame>12 months following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment discontinuation due to treatment success</measure>
    <time_frame>12 months following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (FEV1, growth parameters, CFQ-R)</measure>
    <time_frame>12 months following end of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF patients</arm_group_label>
    <description>Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples collected may include serum, sputum, whole blood, breath, urine, and NTM isolates.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female subjects with CF age 6 years and older with a confirmed diagnosis of NTM
        disease who are initiating treatment for NTM.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previous participation in PREDICT and diagnosis of NTM disease for the same species of
             NTM

          2. Intention to treat for NTM disease for M. avium complex or M. abscessus complex

          3. Written informed consent (and assent when applicable) obtained from participant or
             participant's legal representative

          4. Signed informed consent to participate in data submission to the CFF Patient Registry

          5. Be willing and able to initiate treatment for NTM and to adhere to study procedures in
             the context of clinical care, and other protocol requirements

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Has any other condition that, in the opinion of the Site Investigator/designee, would
             preclude informed consent or assent, make study participation unsafe, complicate
             interpretation of study outcome data, or otherwise interfere with achieving the study
             objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry A Nick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey Martiniano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Jones, RN</last_name>
    <phone>(303) 398-1265</phone>
    <email>jonesm@njhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meg Anthony, MSW</last_name>
    <phone>(720) 777-2945</phone>
    <email>Meg.Anthony@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CFF Pediatric Program, University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Brand</last_name>
      <phone>205-638-9410</phone>
      <email>kbrand@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>George M Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Anthony, MSW</last_name>
      <phone>720-777-2945</phone>
      <email>Meg.Anthony@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Stacey Martiniano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ellington, RN</last_name>
      <phone>303-270-2333</phone>
      <email>ellingtons@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jerry A Nick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Rykiel</last_name>
      <phone>410-614-1409</phone>
      <email>mrykiel1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Keira Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Kruse</last_name>
      <phone>734-615-3266</phone>
      <email>dmkruse@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Lindsay Caverly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Kramer</last_name>
      <phone>215-305-4675</phone>
      <email>ARK2187@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Emily DiMango, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelsey Haywood</last_name>
      <phone>919-445-2855</phone>
      <email>kelsey_haywood@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Goralski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, The University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Keller</last_name>
      <phone>214-648-2817</phone>
      <email>Ashley.Keller@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Raksha Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Pediatric Program Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon McNamara</last_name>
      <phone>206-987-3921</phone>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CFF Adult Program, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Gambol</last_name>
      <phone>206-543-7382</phone>
      <email>TGambol@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Moira Aitken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jerry A. Nick, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Nontuberculous Mycobacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

